The Turkish Version Of The Brief-Caffeine Expectancy Questionnaire
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06038903 |
Recruitment Status :
Completed
First Posted : September 15, 2023
Last Update Posted : February 20, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Caffeine Adaptation Expectations Language | Other: caffeine consumption expectation |
Study Type : | Observational [Patient Registry] |
Actual Enrollment : | 300 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Target Follow-Up Duration: | 30 Days |
Official Title: | Evaluation of The Psychometric Properties of The Turkish Version of The Brief-Caffeine Expectancy Questionnaire (B-CaffeQ): An Adaptation Study in Recreationally Active Individuals |
Actual Study Start Date : | September 8, 2023 |
Actual Primary Completion Date : | October 10, 2023 |
Actual Study Completion Date : | October 15, 2023 |
Group/Cohort | Intervention/treatment |
---|---|
EFA group
This group for exploratory factor analysis (EFA)
|
Other: caffeine consumption expectation
The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption. |
CFA group
This group for confirmatory factor analysis (CFA)
|
Other: caffeine consumption expectation
The group to which the Short-form caffeine expectation questionnaire (B-CaffeQ) was applied, which evaluated the expectations from caffeine consumption. |
- the Breif-Caffeine Expectancy Questionnaire (B-CaffeQ) [ Time Frame: two weeks ]Brief-Caffeine Expectancy Questionnaire, which is a simplified version of the caffeine expectancy questionnaire developed by Huntley and Juliano (2012), will be included. This questionnaire, whish has been simplified by Kearns et al. (2018) by carrying out validity and reliability studies, has a 7-factor structure, consisting of 20 articles (Huntley & Juliano, 2012; Kearns et al., 2018). The rating of this questionnaire, which was created in six Likert type, was defined as "1 = Strongly Disagree" to "6= Strongly Agree". In the last part of the questionnaire, there will be questions from which the demographic information of the participants such as age, gender, educational status, etc. obtaine.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Aged between 18 and 60
- Physical health individuals
Exclusion Criteria:
- Heart disease
- Using of pacemaker
- Epilepsy
- Transient ischemic attack
- Stroke or similar nervous disorders
- Psychiatric disease
- Cardio-pulmonary diseases
- Pregnancy
- Drug using that affect the heart rate and blood pressure
- Systemic, neuroplastic, inflammation disorders
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06038903
Turkey | |
Eskişehir Technical University | |
Eskişehir, Tepebaşı, Turkey, 26555 |
Principal Investigator: | celil kaçoğlu, assoc. prof. | Eskişehir Tecnical University |
Responsible Party: | Celil Kaçoğlu, Associated profesor, Eskisehir Technical University |
ClinicalTrials.gov Identifier: | NCT06038903 |
Other Study ID Numbers: |
EskisehirTU-SBF-CK-02 |
First Posted: | September 15, 2023 Key Record Dates |
Last Update Posted: | February 20, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
expectation caffeine Brief-Caffeine Expectancy Questionnaire Language adaptation study |
Caffeine Central Nervous System Stimulants Physiological Effects of Drugs Phosphodiesterase Inhibitors Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents |